https://www.optimumcomms.com/wp-content/uploads/2025/09/AMS.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-27 08:51:022025-10-27 08:51:02AMS to participate in upcoming investor conferences in November and December
https://www.optimumcomms.com/wp-content/uploads/2025/09/AMS.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-27 08:51:022025-10-27 08:51:02AMS to participate in upcoming investor conferences in November and December
Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Recognizes the potential of HDP-101 to address a serious…

Novo Holdings to make changes to its Board of Directors
Novo Holdings plans to elect Lars Green, former CFO of Novozymes…

The Novo Nordisk Foundation proposes new candidates for election as members of the Board of Directors of Novo Nordisk A/S
Earlier today, Novo Nordisk A/S announced that it has called…

Biocomposites launches SYNICEM™ spacers in the U.S.
Ready-to-use preformed antibiotic loaded spacers for hip, knee…

Astraveus further strengthens world class leadership team to advance development of Lakhesys Benchtop Cell Factory™
Highly experienced hires bring robust operational and technical…

Novo Holdings co-leads €40m fundraising to scale MATR Foods’ production of organic plant-based meat alternatives
Financing co-led by Novo Holdings and EIFO
Proceeds to…

Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials
Financing will support the full execution of Phase Ib proof-of-mechanism…

Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications
Exclusive license via Yeda to two Weizmann Institute patent…

Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points
Brings over 35 years of oncology drug development experience,…

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV
Results presented today at ESGCT 2025
PARIS, France, LUND,…

Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
Leading ADC candidate HDP-101 continues to demonstrate favorable…

Glen Clova Scientific Announces Clinical Advisory Board for its Immuno-Dermatology Pipeline
Dundee, UK, 09 October 2025 – Glen Clova Scientific (GCS),…

Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025
– Dr Paul Brennan to present on the association of early biomarker…

Hansa Biopharma on 2nd October announced the raise of approximately USD 71 million through directed share issue
Hansa Biopharma on 2nd October announced the raise of approximately…

Optimum Strategic Communications to Host 17th Annual Healthcare Investor Conference
How can companies with promising science secure the capital…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York